{"id":"https://openalex.org/W7225758361","doi":"https://doi.org/10.1182/bloodadvances.2026020917","title":"CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study","display_name":"CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225758361","doi":"https://doi.org/10.1182/bloodadvances.2026020917"},"language":"en","primary_location":{"id":"doi:10.1182/bloodadvances.2026020917","doi":"https://doi.org/10.1182/bloodadvances.2026020917","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2026020917","pdf_url":null,"source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1182/bloodadvances.2026020917","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102014552","display_name":"Michael John Dickinson","orcid":"https://orcid.org/0000-0002-1492-5966","observed_orcids":["https://orcid.org/0000-0002-1492-5966"]},"institutions":[{"id":"https://openalex.org/I1320473756","display_name":"The Royal Melbourne Hospital","ror":"https://ror.org/005bvs909","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I1320473756","https://openalex.org/I4210158168"]},{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Michael J. Dickinson","raw_affiliation_strings":["Peter MacCallum Cancer Center and Royal Melbourne Hospital, Australia"],"raw_orcid":"https://orcid.org/0000-0002-1492-5966","affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Center and Royal Melbourne Hospital, Australia","institution_ids":["https://openalex.org/I1320473756","https://openalex.org/I2800555584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047711932","display_name":"Koorosh Korfi","orcid":"https://orcid.org/0000-0001-5009-4509","observed_orcids":["https://orcid.org/0000-0001-5009-4509"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Koorosh Korfi","raw_affiliation_strings":["Pharma Research and Early Development, Roche Innovation Center Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research and Early Development, Roche Innovation Center Zurich, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067329171","display_name":"Martin Hutchings","orcid":"https://orcid.org/0000-0003-3873-1741","observed_orcids":["https://orcid.org/0000-0003-3873-1741"]},"institutions":[{"id":"https://openalex.org/I124055696","display_name":"University of Copenhagen","ror":"https://ror.org/035b05819","country_code":"DK","type":"education","lineage":["https://openalex.org/I124055696"]},{"id":"https://openalex.org/I2802709434","display_name":"Rigshospitalet","ror":"https://ror.org/03mchdq19","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802709434","https://openalex.org/I4210145385"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Martin Hutchings","raw_affiliation_strings":["Department of Hematology and Phase 1 Unit, Rigshospitalet and University of Copenhagen, Denmark"],"raw_orcid":"https://orcid.org/0000-0003-3873-1741","affiliations":[{"raw_affiliation_string":"Department of Hematology and Phase 1 Unit, Rigshospitalet and University of Copenhagen, Denmark","institution_ids":["https://openalex.org/I124055696","https://openalex.org/I2802709434"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051605599","display_name":"Franck Morschhauser","orcid":"https://orcid.org/0000-0002-3714-9824","observed_orcids":["https://orcid.org/0000-0002-3714-9824"]},"institutions":[{"id":"https://openalex.org/I3018718406","display_name":"Centre Hospitalier Universitaire de Lille","ror":"https://ror.org/02ppyfa04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Franck Morschhauser","raw_affiliation_strings":["Department of Hematology, Centre Hospitalier Universitaire Lille, France"],"raw_orcid":"https://orcid.org/0000-0002-3714-9824","affiliations":[{"raw_affiliation_string":"Department of Hematology, Centre Hospitalier Universitaire Lille, France","institution_ids":["https://openalex.org/I3018718406"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042459008","display_name":"Carmelo Carlo\u2010Stella","orcid":"https://orcid.org/0000-0003-3144-0124","observed_orcids":["https://orcid.org/0000-0003-3144-0124"]},"institutions":[{"id":"https://openalex.org/I1339471597","display_name":"Humanitas University","ror":"https://ror.org/020dggs04","country_code":"IT","type":"education","lineage":["https://openalex.org/I1339471597"]},{"id":"https://openalex.org/I4210163047","display_name":"IRCCS Humanitas Research Hospital","ror":"https://ror.org/05d538656","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210163047"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Carmelo Carlo-Stella","raw_affiliation_strings":["Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Italy"],"raw_orcid":"https://orcid.org/0000-0003-3144-0124","affiliations":[{"raw_affiliation_string":"Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Italy","institution_ids":["https://openalex.org/I1339471597","https://openalex.org/I4210163047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090759974","display_name":"Lorenzo Falchi","orcid":"https://orcid.org/0000-0003-1531-3838","observed_orcids":["https://orcid.org/0000-0003-1531-3838"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lorenzo Falchi","raw_affiliation_strings":["Lymphoma Service, Memorial Sloan Kettering Cancer Center, United States"],"raw_orcid":"https://orcid.org/0000-0003-1531-3838","affiliations":[{"raw_affiliation_string":"Lymphoma Service, Memorial Sloan Kettering Cancer Center, United States","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016048836","display_name":"Paolo Fabrizio Caimi","orcid":"https://orcid.org/0000-0003-1436-0464","observed_orcids":["https://orcid.org/0000-0003-1436-0464"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paolo F. Caimi","raw_affiliation_strings":["Cleveland Clinic Cancer Institute, Cleveland, Ohio, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Cancer Institute, Cleveland, Ohio, United States","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029160106","display_name":"Natalie Dimier","orcid":"https://orcid.org/0000-0002-8537-4962","observed_orcids":["https://orcid.org/0000-0002-8537-4962"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I4210113058","display_name":"Roche (United Kingdom)","ror":"https://ror.org/024tgbv41","country_code":"GB","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210113058"]}],"countries":["CH","GB"],"is_corresponding":false,"raw_author_name":"Natalie Dimier","raw_affiliation_strings":["Pharma Research and Early Development, Roche Innovation Center, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research and Early Development, Roche Innovation Center, United Kingdom","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I4210113058"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161405829","display_name":"Lance Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210113058","display_name":"Roche (United Kingdom)","ror":"https://ror.org/024tgbv41","country_code":"GB","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210113058"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lance Smith","raw_affiliation_strings":["Pharma Research and Early Development, Roche Innovation Center, Welwyn, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research and Early Development, Roche Innovation Center, Welwyn, United Kingdom","institution_ids":["https://openalex.org/I4210113058"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087030773","display_name":"Matt Whayman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210113058","display_name":"Roche (United Kingdom)","ror":"https://ror.org/024tgbv41","country_code":"GB","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210113058"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matt Whayman","raw_affiliation_strings":["Pharma Research and Early Development, Roche Innovation Center, Welwyn, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research and Early Development, Roche Innovation Center, Welwyn, United Kingdom","institution_ids":["https://openalex.org/I4210113058"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084056228","display_name":"Johannes Sam","orcid":"https://orcid.org/0000-0002-7455-0609","observed_orcids":["https://orcid.org/0000-0002-7455-0609"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Johannes Sam","raw_affiliation_strings":["Pharma Research and Early Development, Roche Innovation Center Zurich, Switzerland"],"raw_orcid":"https://orcid.org/0000-0002-7455-0609","affiliations":[{"raw_affiliation_string":"Pharma Research and Early Development, Roche Innovation Center Zurich, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161380138","display_name":"Abiraj Keelara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Abiraj Keelara","raw_affiliation_strings":["Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003079347","display_name":"Candice Jamois","orcid":"https://orcid.org/0000-0001-7018-9687","observed_orcids":["https://orcid.org/0000-0001-7018-9687"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Candice Jamois","raw_affiliation_strings":["Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032959826","display_name":"Sabine Wilson","orcid":"https://orcid.org/0009-0008-5594-9519","observed_orcids":["https://orcid.org/0009-0008-5594-9519"]},"institutions":[{"id":"https://openalex.org/I4210113058","display_name":"Roche (United Kingdom)","ror":"https://ror.org/024tgbv41","country_code":"GB","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210113058"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sabine Wilson","raw_affiliation_strings":["Computational Sciences Center of Excellence, Roche Innovation Center Welwyn, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Computational Sciences Center of Excellence, Roche Innovation Center Welwyn, United Kingdom","institution_ids":["https://openalex.org/I4210113058"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104206514","display_name":"Zhiwen Jiang","orcid":"https://orcid.org/0009-0003-9865-209X","observed_orcids":["https://orcid.org/0009-0003-9865-209X"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Zhiwen Jiang","raw_affiliation_strings":["Computational Sciences Center of Excellence, F. Hoffmann-La Roche Basel, Basel, Switzerland"],"raw_orcid":"https://orcid.org/0009-0009-1797-4921","affiliations":[{"raw_affiliation_string":"Computational Sciences Center of Excellence, F. Hoffmann-La Roche Basel, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115006309","display_name":"Jeremy Gallien","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I4405285948","display_name":"Roche Pharma (Schweiz) AG (Switzerland)","ror":"https://ror.org/00rkxt385","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4405285948"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Jeremy Gallien","raw_affiliation_strings":["Pharma Development, Roche Innovation Center Basel, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Development, Roche Innovation Center Basel, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I4405285948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106014809","display_name":"Iris Martinez Quetglas","orcid":"https://orcid.org/0009-0009-9558-1517","observed_orcids":["https://orcid.org/0009-0009-9558-1517"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Iris Martinez-Quetglas","raw_affiliation_strings":["Pharma Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland"],"raw_orcid":"https://orcid.org/0009-0009-9558-1517","affiliations":[{"raw_affiliation_string":"Pharma Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005030023","display_name":"Heather J. Hinton","orcid":"https://orcid.org/0000-0002-1028-0558","observed_orcids":["https://orcid.org/0000-0002-1028-0558"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Heather Hinton","raw_affiliation_strings":["Product Development, Roche Innovation Center Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Product Development, Roche Innovation Center Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032720171","display_name":"Isabel Prieto Gonz\u00e1lez-Albo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210113058","display_name":"Roche (United Kingdom)","ror":"https://ror.org/024tgbv41","country_code":"GB","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210113058"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Isabel Prieto Gonzalez-Albo","raw_affiliation_strings":["Product Development, Roche Innovation Center Welwyn, Welwyn, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Product Development, Roche Innovation Center Welwyn, Welwyn, United Kingdom","institution_ids":["https://openalex.org/I4210113058"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091508845","display_name":"Francesca Michielin","orcid":"https://orcid.org/0009-0007-0153-2139","observed_orcids":["https://orcid.org/0009-0007-0153-2139"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I4405285948","display_name":"Roche Pharma (Schweiz) AG (Switzerland)","ror":"https://ror.org/00rkxt385","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4405285948"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Francesca Michielin","raw_affiliation_strings":["Pharma Development, Roche Innovation Center Basel, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Development, Roche Innovation Center Basel, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I4405285948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076521943","display_name":"Katharina Lechner","orcid":"https://orcid.org/0000-0002-3582-3512","observed_orcids":["https://orcid.org/0000-0002-3582-3512"]},"institutions":[{"id":"https://openalex.org/I4210094361","display_name":"Roche Pharma AG (Germany)","ror":"https://ror.org/00sh68184","country_code":"DE","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210094361"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Katharina Lechner","raw_affiliation_strings":["Pharma Research and Early Development, Roche Innovation Center Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research and Early Development, Roche Innovation Center Munich, Germany","institution_ids":["https://openalex.org/I4210094361"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5010723896","display_name":"Giuseppe Gritti","orcid":"https://orcid.org/0000-0002-6789-5123","observed_orcids":["https://orcid.org/0000-0002-6789-5123"]},"institutions":[{"id":"https://openalex.org/I4210094361","display_name":"Roche Pharma AG (Germany)","ror":"https://ror.org/00sh68184","country_code":"DE","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210094361"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Giuseppe Gritti","raw_affiliation_strings":["Pharma Research and Early Development, Roche Innovation Center Munich, Germany"],"raw_orcid":"https://orcid.org/0000-0002-6789-5123","affiliations":[{"raw_affiliation_string":"Pharma Research and Early Development, Roche Innovation Center Munich, Germany","institution_ids":["https://openalex.org/I4210094361"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":13,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.7476000189781189,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.7476000189781189,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.20389999449253082,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.009999999776482582,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.6642000079154968},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6065999865531921},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5964999794960022},{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.5638999938964844},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5073000192642212},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4772999882698059},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.4415999948978424},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.42570000886917114},{"id":"https://openalex.org/C3020495827","wikidata":"https://www.wikidata.org/wiki/Q426141","display_name":"Bispecific antibody","level":4,"score":0.41269999742507935},{"id":"https://openalex.org/C51785407","wikidata":"https://www.wikidata.org/wiki/Q2627568","display_name":"Effector","level":2,"score":0.4124000072479248},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.39899998903274536},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39070001244544983},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.38929998874664307},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3718000054359436},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.36329999566078186},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3402999937534332},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.3246999979019165},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.32409998774528503},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.310699999332428},{"id":"https://openalex.org/C148125776","wikidata":"https://www.wikidata.org/wiki/Q1622348","display_name":"CD28","level":4,"score":0.30880001187324524},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.3073999881744385},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.2867000102996826},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.27129998803138733},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.26600000262260437}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/bloodadvances.2026020917","doi":"https://doi.org/10.1182/bloodadvances.2026020917","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2026020917","pdf_url":null,"source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1182/bloodadvances.2026020917","doi":"https://doi.org/10.1182/bloodadvances.2026020917","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2026020917","pdf_url":null,"source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"RO7443904":[0],"(CD19-CD28)":[1],"is":[2],"a":[3,29,220,232],"novel":[4],"costimulatory":[5],"bispecific":[6,21],"antibody":[7,22],"designed":[8],"to":[9,67,95,164],"enhance":[10],"T-cell":[11,203,238],"activation":[12],"and":[13,77,104,117,123,140,174,181,186,191,201,205,224],"anti-tumor":[14],"activity":[15],"when":[16],"combined":[17],"with":[18,41,52,172,217,241],"the":[19,78,107,213],"CD20xCD3":[20],"glofitamab.":[23],"We":[24],"report":[25],"primary":[26,99],"results":[27],"from":[28],"phase":[30],"1":[31,85],"dose-escalation":[32],"trial":[33],"(BP43131;":[34],"NCT05219513)":[35],"evaluating":[36],"this":[37,48],"combination":[38,168,214],"in":[39,193,208,228,244],"patients":[40,51],"relapsed/refractory":[42,229],"B-cell":[43],"non-Hodgkin":[44],"lymphoma":[45],"(B-NHL).":[46],"In":[47,211],"study,":[49],"52":[50],"heavily":[53],"pre-treated":[54],"B-NHL":[55],"(aggressive,":[56],"n":[57,61],"=":[58,62],"33;":[59],"indolent,":[60],"19)":[63],"received":[64],"obinutuzumab":[65],"pretreatment":[66],"mitigate":[68],"cytokine":[69,132],"release":[70,133],"syndrome,":[71],"glofitamab":[72,144,216],"step-up":[73,145],"dosing":[74],"(2.5/10/30":[75],"mg),":[76],"addition":[79],"of":[80,106,179,215],"CD19-CD28":[81,199,218],"(initiated":[82],"on":[83],"cycle":[84,89],"day":[86,91],"10":[87],"or":[88],"2":[90],"8),":[92],"for":[93,183,188,236],"up":[94],"12":[96],"cycles.":[97],"The":[98,125,167],"objectives":[100,119],"were":[101,159],"safety,":[102],"tolerability,":[103],"identification":[105],"maximum":[108],"tolerated":[109],"dose,":[110],"which":[111,136],"was":[112,131,137],"not":[113],"reached.":[114],"Key":[115],"secondary":[116],"exploratory":[118],"included":[120],"efficacy,":[121,171],"pharmacokinetics,":[122],"pharmacodynamics.":[124],"most":[126],"common":[127],"adverse":[128],"event":[129],"(AE)":[130],"syndrome":[134],"(53.8%),":[135],"predominantly":[138],"low-grade":[139],"occurred":[141],"primarily":[142],"during":[143],"(grade":[146],"1:":[147],"36.5%;":[148],"grade":[149,152],"2:":[150],"19.2%;":[151],"4:":[153],"3.8%).":[154],"Five":[155],"fatal":[156],"AEs":[157],"(9.6%)":[158],"reported,":[160],"all":[161],"considered":[162],"non-related":[163],"study":[165],"treatment.":[166],"demonstrated":[169],"substantial":[170],"objective":[173],"complete":[175],"response":[176],"rates":[177],"(ORR/CRR)":[178],"63.6%":[180],"42.4%":[182],"aggressive":[184],"B-NHL,":[185,230],"89.5%":[187],"both":[189],"ORR":[190],"CRR":[192],"indolent":[194],"B-NHL.":[195,245],"Pharmacodynamic":[196],"analyses":[197],"confirmed":[198],"enhanced":[200],"sustained":[202],"proliferation":[204],"effector":[206],"functions":[207],"peripheral":[209],"blood.":[210],"conclusion,":[212],"had":[219],"manageable":[221],"safety":[222],"profile":[223],"promising":[225],"early":[226],"efficacy":[227],"providing":[231],"strong":[233],"clinical":[234],"proof-of-concept":[235],"enhancing":[237],"engager":[239],"therapy":[240],"CD28":[242],"costimulation":[243]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}